Details for New Drug Application (NDA): 213560
✉ Email this page to a colleague
The generic ingredient in HALOBETASOL PROPIONATE is halobetasol propionate; tazarotene. There are nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the halobetasol propionate; tazarotene profile page.
Summary for 213560
| Tradename: | HALOBETASOL PROPIONATE |
| Applicant: | Quagen |
| Ingredient: | halobetasol propionate |
| Patents: | 0 |
Pharmacology for NDA: 213560
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Suppliers and Packaging for NDA: 213560
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| HALOBETASOL PROPIONATE | halobetasol propionate | OINTMENT;TOPICAL | 213560 | ANDA | QUAGEN PHARMACEUTICALS LLC | 70752-119 | 70752-119-02 | 1 TUBE in 1 CARTON (70752-119-02) / 15 g in 1 TUBE |
| HALOBETASOL PROPIONATE | halobetasol propionate | OINTMENT;TOPICAL | 213560 | ANDA | QUAGEN PHARMACEUTICALS LLC | 70752-119 | 70752-119-04 | 1 TUBE in 1 CARTON (70752-119-04) / 50 g in 1 TUBE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | OINTMENT;TOPICAL | Strength | 0.05% | ||||
| Approval Date: | Oct 6, 2020 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
